Apellis Strategy and Business Model

Executive Overview

Apellis is a U.S. biopharmaceutical company focused on diseases driven by dysfunction in the complement cascade, a part of the immune system. Founded in 2009 and headquartered in Waltham, Massachusetts, Apellis has built its franchise around pegcetacoplan, a therapy that targets complement component C3. That scientific choice is central to the company’s strategy: rather than intervening later in the pathway, Apellis aims to treat complement-mediated disease by acting at a broader control point. Commercially, the company now spans two specialist markets. In rare hematology, it markets EMPAVELI for paroxysmal nocturnal hemoglobinuria (PNH). In ophthalmology, it markets SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration, a much larger but operationally more demanding market. That mix matters because it gives Apellis exposure to both orphan-disease economics and the scale of retina clinics and office-administered drugs. Apellis is primarily a U.S. commercial company, with additional international reach through partners for certain systemic indications. The latest annual revenue is shown in the live company snapshot below; by FY2023, Apellis had clearly shifted from development-stage biotech to commercial-stage biopharma.

Apellis at a Glance

Logo
Common name	Apellis
Full legal name	Apellis Pharmaceuticals, Inc.
Headquarters	Waltham, Massachusetts, United States
Ownership	Public company
Ticker	APLS
Exchange	NASDAQ
Market Cap	#N/A
Revenue (FY2024)	#N/A
Founding / major historical milestones	Founded in 2009; Nasdaq IPO in 2017; FDA approval of EMPAVELI for PNH in 2021; FDA approval of SYFOVRE for geographic atrophy in 2023
Industry or industries	Biopharmaceuticals; complement-mediated diseases; ophthalmology; rare disease
Key products or services	SYFOVRE, EMPAVELI, and a complement-focused development pipeline
Geographic footprint	United States direct commercial operations; partner-led international reach for certain systemic indications; global clinical development activities
Business segments as officially reported	One reportable segment
Company website	https://www.apellis.com

1. What Is the Strategy of Apellis?

Apellis’s public materials through mid-2024 point to a clear corporate thesis: build a differentiated complement franchise by targeting C3, translate that science into specialist-market products, and use the commercial success of approved drugs to fund broader expansion in complement-mediated disease. Using the Playing to Win framework, the strategy can be expressed as follows.

1a. What is the winning aspiration of Apellis?

Apellis’s winning aspiration is to become a leading commercial biopharma company in complement-mediated disease, not just a single-product biotech. Public communications consistently frame the company around transforming outcomes in diseases driven by complement dysfunction. In practical terms, “winning” means establishing pegcetacoplan as a meaningful treatment platform across multiple indications, turning approved assets into durable franchises, and using those franchises to support additional pipeline development. Apellis has not generally emphasized a long-range public revenue target in the way some large pharmaceutical companies do; instead, the concrete aspiration visible in filings and investor materials is franchise creation: prove that C3 inhibition can support repeatable commercial and clinical success in ophthalmology, rare hematology, and adjacent complement-driven diseases.
1b. Where does Apellis play?

Apellis plays in diseases where complement biology appears central and where specialist prescribing channels can support premium-priced, evidence-driven therapies. As of mid-2024, that meant two main commercial arenas: retina, through geographic atrophy secondary to age-related macular degeneration, and rare hematology, through paroxysmal nocturnal hemoglobinuria. The company also has public development activity in rare kidney diseases such as C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. Geographically, Apellis’s strongest direct commercial presence is in the United States. Outside the U.S., it has used partnerships, especially for systemic pegcetacoplan, rather than trying to build a fully global infrastructure all at once.
1c. How does Apellis plan to win?

Apellis plans to win through mechanism-based differentiation and focused specialist execution. Its scientific pitch is that C3 inhibition may address disease biology more broadly than therapies that intervene further downstream in the complement pathway. In PNH, that differentiated EMPAVELI from established C5 inhibitors by addressing unmet needs such as ongoing anemia and extravascular hemolysis. In geographic atrophy, Apellis sought first-mover advantage with the first FDA-approved treatment in the category. Commercially, the company’s approach is not broad primary-care scale; it is depth in narrow specialist channels, supported by medical affairs, reimbursement support, evidence generation, and careful safety communication. That is especially important in retina, where physician confidence, office workflow, and buy-and-bill economics shape adoption.
1d. What capabilities must Apellis have in place?

To execute this strategy, Apellis needs a specific set of capabilities: deep complement biology and translational medicine; strong clinical-development execution in rare disease and ophthalmology; regulatory skill across both accelerated and large-specialist markets; dependable manufacturing and sterile supply for chronic biologic therapy; sophisticated pharmacovigilance; and specialist commercialization in hematology and retina. It also needs payer-access and reimbursement capabilities because product adoption depends not only on clinical demand but also on smooth patient onboarding, hub services, coding, coverage, and office economics. Finally, partnership management matters because some ex-U.S. value is created through collaborators rather than wholly owned infrastructure.
1e. What management systems does Apellis require?

Apellis requires management systems that are more typical of a commercial-stage biotech than an early research company. These include portfolio-governance and stage-gate decision systems for pipeline allocation; quality and compliance systems for manufacturing, distribution, and adverse-event reporting; launch dashboards that track starts, persistence, reimbursement, and account-level demand; and disciplined capital-allocation processes that balance R&D, medical affairs, and commercial spend. In Apellis’s case, post-marketing safety systems are especially important because retina adoption can be highly sensitive to rare but serious safety events. The company also needs strong cross-functional governance linking R&D, technical operations, medical affairs, and commercial teams because both approved products rely on the same core molecule but serve different care pathways.

2. What Are the Current Strategic Initiatives of Apellis?

Public materials in 2023 and 2024 suggest that Apellis’s near-term agenda has been centered on turning scientific validation into durable commercial execution. The most important announced and visible initiatives include the following.

Scale SYFOVRE in geographic atrophy. Following the 2023 U.S. approval, Apellis’s most important strategic initiative has been to build SYFOVRE into a durable retina franchise. That includes physician education, market-access work, real-world evidence generation, and efforts to support confidence in patient selection and dosing cadence.
Manage safety communication and pharmacovigilance in retina. After rare post-launch reports of retinal vasculitis and related events, Apellis had to make safety stewardship a strategic priority, not just a compliance task. In practice, that means intensive medical affairs activity, surveillance, transparent communication with retina specialists, and continued evidence development.
Defend and expand EMPAVELI in PNH. EMPAVELI remains important strategically even though geographic atrophy is the larger market. Apellis has continued positioning the drug around unmet need in patients inadequately served by C5 inhibitors and as a differentiated option in a market that is becoming more competitive.
Advance late-stage and registrational work in complement-mediated kidney disease. Apellis has continued to invest in systemic pegcetacoplan beyond PNH, particularly in rare kidney diseases such as C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis. This matters because it tests whether Apellis can create a broader complement franchise rather than a two-product company.
Use partnership structures to extend reach outside the U.S. For systemic pegcetacoplan, Apellis has used partners such as Sobi in markets outside the U.S. That allows international expansion without carrying the full fixed cost of a broad global commercial buildout.
Strengthen manufacturing, supply, and operational readiness. With two approved products and a larger commercial footprint, Apellis has had to operate more like a scaled biopharma company. Supply reliability, sterile manufacturing, release testing, inventory planning, and distribution continuity are now strategic enablers, not background functions.

3. What Is the Business Model of Apellis?

Apellis’s business model is built around discovering, developing, and commercializing high-value specialty drugs for chronic complement-mediated diseases. What customers ultimately buy is not a commodity molecule; they buy clinically meaningful disease control in settings where alternatives are limited, imperfect, or newly emerging. In practice, the economic customer varies by product. Physicians prescribe, patients receive therapy, sites of care administer or support it, and payers reimburse it.

The revenue model is primarily repeat-driven. SYFOVRE is an office-administered retina therapy used on an ongoing schedule, so revenue depends on patient starts, persistence, dosing frequency, and practice reimbursement. EMPAVELI is also used chronically, which makes the rare-disease franchise recurring rather than one-time. In addition to direct product sales, Apellis also has collaboration-related economics tied to partners in certain geographies or indications.

Pricing power exists because the products address serious diseases and are backed by specialized clinical evidence, but it is not unlimited. Net realized pricing depends on payer coverage, government reimbursement, specialty distribution economics, and, in retina, whether practices are comfortable carrying inventory under buy-and-bill workflows. The business mix matters because ophthalmology can offer larger volume but requires heavier field execution and safety management, while rare disease tends to involve fewer prescribers, deeper patient support, and often higher revenue per patient.

Gross margin is supported by branded biopharma economics but influenced by manufacturing complexity, external production partners, royalties or collaboration economics, and scale. Operating margin is heavily affected by R&D and commercial spend. Cash generation improves as mature product revenue grows faster than launch and development expense, but Apellis still has a portfolio that requires ongoing investment rather than harvest-mode capital allocation.

4. What Products and/or Services Does Apellis Sell?

Apellis’s commercial portfolio is concentrated, and that concentration is strategically important because both marketed products are based on pegcetacoplan.

SYFOVRE. SYFOVRE is Apellis’s intravitreal formulation of pegcetacoplan for geographic atrophy secondary to age-related macular degeneration in the United States. It is the company’s largest strategic asset because it opened the retina market and gave Apellis access to a substantially larger patient population than PNH.
EMPAVELI. EMPAVELI is Apellis’s systemic pegcetacoplan product for adults with paroxysmal nocturnal hemoglobinuria in the United States. It established the company’s first rare-disease commercial franchise and remains important as both a revenue source and proof point for the C3 platform.
Ex-U.S. systemic pegcetacoplan economics. Outside the U.S., certain systemic pegcetacoplan rights have been commercialized through partners rather than wholly by Apellis. That means Apellis’s economic exposure can include milestones, royalties, and collaboration-related revenue rather than only direct product sales.
Pipeline programs. Apellis also offers investors and potential partners a pipeline of complement-focused programs, particularly in rare kidney disease and other complement-mediated conditions. These are not yet core revenue generators, but they are strategically important because they determine whether Apellis becomes a broader platform company or remains heavily dependent on two approved assets.

As of mid-2024, SYFOVRE appeared to be the main growth engine, while EMPAVELI remained important for diversification, cash contribution, and credibility in systemic complement disease.

5. What Are the Key Competitors or Peers of Apellis?

Apellis competes directly in PNH and geographic atrophy and, more broadly, with other companies building complement-focused pipelines. The relevant competitor set therefore includes both product-level rivals and platform peers.

AstraZeneca / Alexion. The clearest direct competitor in PNH. Soliris and Ultomiris established the modern complement market in PNH and remain major comparators for EMPAVELI.
Novartis. Novartis is a significant complement competitor through Fabhalta in PNH and through its broader complement and renal-disease development activity.
Astellas / Iveric Bio. A direct competitor in geographic atrophy through IZERVAY. In practice, this is one of Apellis’s most important competitive relationships because both products compete for the same retina specialists and patient pool.
Roche / Chugai. Roche is relevant in two ways: it has complement activity in PNH through crovalimab and it is a major ophthalmology company with strong specialist-channel capabilities.
Regeneron. Regeneron is not the same kind of direct GA competitor as Astellas, but it is a powerful retina peer because of its deep relationships with retinal specialists and its presence in office-administered ophthalmology.
Annexon. A complement-focused biotech peer. It is less of a direct same-indication competitor than a scientific and investor-set comparable.
Omeros. Another complement-pathway peer, especially relevant when comparing development approaches in rare, immunology-linked disease.

The competitive picture differs by franchise. In PNH, Apellis competes against well-established complement incumbents and newer alternatives. In geographic atrophy, competition is more about specialist confidence, safety profile, office workflow, and evidence interpretation than classic mass-market share battles.

6. What Is the Marketing Strategy of Apellis?

Apellis’s marketing strategy is specialist-focused, evidence-heavy, and closely tied to medical affairs. This is not a consumer packaged goods model and not primarily a broad direct-to-consumer model. The company markets to a relatively small number of high-value prescribers and treatment centers, especially retina specialists and hematologists.

In geographic atrophy, marketing has included a large market-creation component because GA historically had no approved treatment. That means Apellis has had to educate physicians not only on its own product but also on treatment rationale, patient identification, expected efficacy, dosing tradeoffs, and office workflow. Congress presence, key opinion leader engagement, peer-to-peer education, and field medical support are therefore unusually important. After the emergence of rare retinal safety concerns, communication quality became even more central to the brand’s commercial trajectory.

In PNH, the marketing model is narrower and more account-specific. The audience is smaller, treatment decisions are highly clinical, and patient support services matter as much as promotion. Across both franchises, payer support, reimbursement education, and patient access services are core parts of marketing effectiveness. In other words, for Apellis, marketing is not just messaging; it is the coordinated management of evidence, trust, access, and specialist workflow.

7. What Are the Key Customer Segments of Apellis?

Apellis serves a concentrated set of specialist-market customer segments rather than a broad, diversified healthcare customer base.

Retina specialists and ophthalmology practices. These are the key prescribers and treatment sites for SYFOVRE. Because the therapy is office-administered, the economics and workflow of the practice matter alongside clinical demand.
Hematologists and PNH treatment centers. These are the main clinical decision-makers for EMPAVELI. The patient population is much smaller than in retina, but the treatment journey is deeper and more service-intensive.
Payers and government reimbursement programs. Insurers, Medicare, and related reimbursement systems are crucial economic stakeholders. In biopharma, the prescriber is not the only customer that matters; payment approval and coverage policy can materially affect realized demand.
Patients and caregivers. They are not always the direct purchaser, but they are central to therapy initiation, persistence, and adherence, especially in chronic treatment settings.
International partners. In markets where Apellis has licensed or partnered rights, the partner becomes an important channel customer and value-creation intermediary.

Apellis is therefore concentrated, not broadly diversified. Its current end markets are attractive because they are specialist-driven and reimbursed, but they are also sensitive to clinical evidence, safety perception, and a relatively small number of prescribing accounts.

8. What Is the Sales Model of Apellis?

Apellis uses a specialty-pharma sales model tailored to each product’s site of care.

For SYFOVRE, the company sells into retina through a direct U.S. field organization that calls on retina specialists and practices. The drug is administered in-office, so the model depends on account-level engagement, coding and reimbursement support, distribution through specialty channels, and confidence that the practice can manage buy-and-bill economics. This makes the sales model highly operational: adoption can depend as much on workflow and reimbursement clarity as on abstract brand awareness.

For EMPAVELI, the model is more typical of rare-disease specialty pharma. Sales efforts focus on a smaller universe of hematologists and treatment centers, while specialty pharmacies, patient services, and onboarding support are important in getting patients started and maintained on therapy.

Outside the U.S. for certain systemic indications, Apellis has used partners rather than building a full direct-sales footprint. That lowers fixed cost but also means some growth is mediated through alliance management rather than purely internal execution.

This channel structure affects growth and pricing in important ways. Apellis benefits from close customer intimacy in specialist accounts, but growth can be lumpy because a relatively small number of practices drive meaningful volume. It also means consultant opportunities are often tied to field-force design, reimbursement workflow, specialty distribution, forecasting, and hub services rather than broad-based consumer marketing.

9. In What Geographies Does Apellis Operate?

As of mid-2024, Apellis was primarily a U.S.-centered operating company. Its headquarters are in Waltham, Massachusetts, and its most important direct commercial activity is in the United States, where it markets SYFOVRE and EMPAVELI.

Internationally, Apellis’s footprint is more selective. For systemic pegcetacoplan in certain ex-U.S. markets, the company has relied on partners such as Sobi rather than replicating its U.S. commercial infrastructure country by country. That means Apellis has global economic exposure without necessarily having a large wholly owned office network in every market.

Its operational geography also differs from its commercial geography. Clinical development can be global, with trial sites and regulatory activity across multiple countries, while manufacturing and supply are handled through a combination of internal oversight and third-party production networks. Apellis does not appear to have a broad owned manufacturing plant footprint like a large pharmaceutical major. The company is therefore geographically focused rather than fully globalized: strong in the U.S., selective abroad, and partner-enabled where scale economics favor collaboration.

10. Who Are the Owners of Apellis?

Apellis is a publicly traded company listed under the ticker APLS. As reflected in public filings through 2024, Apellis did not have a disclosed controlling shareholder. Its ownership base has included specialist healthcare investors and large institutional asset managers. Public filings have shown notable holders such as Baker Bros. Advisors, Vanguard, BlackRock, and EcoR1 Capital, although percentages can change over time. As with most public biopharma companies, ownership is predominantly institutional rather than founder-controlled.

11. How Is Apellis Organized?

Officially, Apellis has reported one reportable segment. That means public financial reporting does not break the company into separate ophthalmology and rare-disease segments in the way a larger diversified pharma company might.

Practically, however, Apellis can be understood as having several operating layers:

Commercial operations, centered on retina and rare disease in the United States
Research and development, focused on complement biology and clinical programs
Medical affairs and pharmacovigilance, which are especially important given the specialist nature of its products
Technical operations, quality, and supply, which oversee manufacturing, release, and distribution through third parties
Corporate functions, including finance, legal, regulatory, and alliance management

This structure is typical of a commercial-stage biotech: simple from an external reporting standpoint, but functionally complex because the company must integrate launch execution, safety oversight, pipeline development, and outsourced supply.

12. How Does Apellis Operate?

On a day-to-day basis, Apellis operates as an integrated development and commercialization company built around a focused mechanism. The company creates value through five linked activities.

Drug development. Apellis identifies complement-mediated diseases, runs clinical trials, analyzes data, and seeks regulatory approvals.
Manufacturing oversight. Like many biopharma companies of its size, Apellis relies heavily on third-party manufacturing and supply partners, while retaining responsibility for quality, forecasting, batch release, and continuity planning.
Specialist commercialization. The company deploys targeted field teams, reimbursement support, patient services, and medical education to drive adoption in narrow but high-value channels.
Medical affairs and safety monitoring. This is a core operating activity, not a support afterthought. Adverse-event monitoring, physician communication, and real-world evidence development are central to sustained product use.
Portfolio and capital management. Management must continually decide how much to invest in launch support, lifecycle evidence, new trials, and geographic expansion.

The biggest operational complexities are not the same as those of a mass-market drug company. For Apellis, the difficult parts include managing specialist trust, ensuring reimbursement fluency in account-level settings, maintaining reliable sterile supply, and balancing the needs of a growing commercial business with the cash demands of biotech R&D.

13. What Are the Growth Opportunities for Apellis?

The most plausible growth opportunities for Apellis, based on public evidence through mid-2024, are concentrated in franchise deepening rather than unrelated diversification.

Drive broader and more durable SYFOVRE adoption. Geographic atrophy is the biggest commercial opportunity in Apellis’s portfolio. Further growth depends on winning physician confidence, improving persistence, broadening the treated patient base, and maintaining access and reimbursement support.
Preserve and expand the PNH franchise. EMPAVELI can still grow if Apellis continues to position it effectively in patients with unmet need relative to C5 inhibitors and navigates competitive entries well.
Extend pegcetacoplan into kidney disease. Success in rare kidney diseases such as C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis would materially widen the company’s addressable market and reduce dependence on two current commercial products.
Increase ex-U.S. value capture through partnerships. Apellis can grow internationally without building a full global infrastructure if it manages partner relationships well and selectively expands where economics justify direct presence.
Leverage platform credibility into adjacent complement opportunities. If the company continues to validate its mechanism, it could create growth through additional indications, lifecycle work, or selective business development.

The main constraints are equally clear. Growth could be limited by retina safety perceptions, tougher competition in both GA and PNH, payer pressure, manufacturing or supply disruptions, and the inherent clinical risk of expanding a platform biotech beyond its first successful indications.

14. What Is the History of Apellis?

Apellis was founded in 2009 and built around the idea that complement inhibition, particularly at C3, could address a broader range of diseases than more downstream approaches. The company spent much of its early life as a research and clinical-stage biotech, developing pegcetacoplan and building evidence in complement-mediated disorders.

In 2017, Apellis went public on Nasdaq, giving it additional capital to fund clinical development and prepare for commercialization. A major turning point came in 2021, when the U.S. Food and Drug Administration approved EMPAVELI for adults with paroxysmal nocturnal hemoglobinuria. That was the company’s first major commercial validation.

The next major inflection point came in 2023, when the FDA approved SYFOVRE for geographic atrophy secondary to age-related macular degeneration. That approval was strategically transformative because it moved Apellis into retina, a much larger market than PNH, but one with greater launch complexity, heavier medical education needs, and more intense post-marketing scrutiny. The company’s recent history has therefore been defined by a transition from focused rare-disease biotech to multi-franchise commercial biopharma, while still retaining the concentration risks typical of a platform company built around one core mechanism.

15. How Does the Supply Chain of Apellis Function?

Supply chain matters meaningfully for Apellis because its products are specialized biologic therapies used chronically and, in the case of SYFOVRE, administered in-office in a sterile ophthalmic setting. Apellis relies substantially on third-party manufacturers and service providers for active pharmaceutical ingredient production, drug product manufacturing, fill-finish, packaging, testing, and distribution, while retaining responsibility for quality oversight and supply continuity.

The supply chain has several strategically important features:

High regulatory sensitivity. Sterile production, batch release, and quality systems are critical because any disruption can affect physician confidence as well as revenue.
Demand-planning complexity. Retina demand can be influenced by practice-level behavior, while rare-disease demand can depend on patient onboarding and persistence. Forecasting therefore matters more than in a simple wholesale model.
Molecule concentration. Because both marketed products are based on pegcetacoplan, Apellis gets some scale benefit from shared core expertise, but it also carries concentration risk if a manufacturing issue affects the common platform.
Partner coordination. In ex-U.S. settings where partners commercialize systemic pegcetacoplan, supply planning and alliance governance become part of the operating challenge.

For Apellis, supply chain is not just a procurement issue. It is directly tied to launch reliability, safety confidence, working capital, and the company’s ability to behave like a scaled commercial biopharma business.

16. What Is the R&D Strategy of Apellis?

Apellis’s R&D strategy is unusually focused for a biotech with commercial ambitions. Rather than scattering capital across many unrelated mechanisms, the company has concentrated on complement biology, especially C3 inhibition, and has sought to use that scientific base across multiple diseases and formulations. That creates both leverage and risk.

The leverage is clear. A focused platform lets Apellis reuse disease-biology expertise, clinical-development know-how, manufacturing knowledge, and safety learning across programs. It also supports a more coherent story to physicians and investors: the company is trying to build a franchise, not a loose collection of projects.

Publicly visible R&D priorities through mid-2024 included:

Post-approval evidence generation for existing commercial products
Lifecycle development around pegcetacoplan in both systemic and ophthalmic settings
Advancement of rare kidney disease programs such as C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis
Selective expansion of the complement platform rather than broad diversification into unrelated therapeutic areas

The tradeoff is concentration. Because the company’s scientific and commercial identity is tightly linked to one mechanism and one lead molecule, the portfolio has less internal hedging than that of a large pharmaceutical company. That makes prioritization discipline especially important.

17. What Is the Finance Strategy of Apellis?

Apellis’s finance strategy is best understood as the capital-allocation discipline of a biotech that has entered commercial scale but still needs to fund meaningful R&D. Historically, the company depended on external capital and partnership economics to fund development. With EMPAVELI and especially SYFOVRE, the model has shifted toward product-generated cash, but not yet toward a low-investment steady-state.

At a high level, Apellis’s financial priorities through 2024 appeared to be:

Fund the SYFOVRE launch and medical support infrastructure
Maintain EMPAVELI commercial execution
Invest in late-stage pipeline opportunities that can broaden the complement franchise
Preserve liquidity and financial flexibility in a business still exposed to clinical, regulatory, and launch risk
Use partnerships selectively to share cost and risk, especially outside the U.S.

Unlike mature pharmaceutical companies, Apellis is not organized around dividends or buybacks. Its finance strategy is reinvestment-led. As revenue scales, gross-to-net management, working-capital control, inventory planning, and expense discipline become more important. Because value is concentrated in a small number of assets, finance strategy also has a strategic role: it determines how aggressively the company can invest in growth while preserving resilience if commercial or clinical outcomes are more volatile than expected.

18. How Companies Like Apellis Leverage Independent Consultants through Umbrex

Companies like Apellis engage Umbrex when they need highly experienced consulting talent without hiring a full traditional consulting team. Umbrex has built a global community of more than 8,000 independent management consultants across more than 50 countries, including alumni of McKinsey, Bain, BCG, and other top firms. For a company like Apellis, that model is useful when leadership needs sharp, project-based support in strategy, operations, commercialization, finance, technology, ERP, or AI while keeping overhead flexible.

Representative projects Umbrex consultants could support for a company like Apellis include:

Geographic atrophy growth strategy: segment retina accounts, map patient flows, and refine territory priorities for SYFOVRE.
Buy-and-bill workflow improvement: redesign reimbursement support and office-economics tools for retina practices.
Post-marketing safety operating model: review pharmacovigilance escalation, medical information workflows, and field communication processes.
PNH franchise defense: assess competitive positioning versus C5 inhibitors and newer complement entrants, and refresh go-to-market priorities.
Rare nephrology launch readiness: build launch plans, patient-journey maps, and key-account strategies for potential kidney-disease indications.
Supply-chain risk assessment: evaluate CMO concentration, sterile fill-finish resilience, release-testing bottlenecks, and contingency planning.
Demand forecasting and sales-and-operations planning: improve forecast accuracy for two specialist products with different care pathways but shared molecule concentration.
Alliance and international strategy: strengthen partner governance, decision rights, and ex-U.S. commercialization economics.
Portfolio prioritization and capital allocation: create a fact-based framework for sequencing investments across commercial support, lifecycle evidence, and pipeline programs.
Business development support: screen adjacent complement or ophthalmology assets, conduct commercial diligence, and evaluate partnership structures.